GCP
RNTX

GSA Capital Partners’s Rein Therapeutics RNTX Stock Holding History

GSA Capital Partners’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,870
Closed -$97K – 1840
2021
Q2 		$97K Sell
3,870
-281
-7% -$7.01K 0.01% 1249
2021
Q1 		$119K Sell
4,151
-177
-4% -$6.07K 0.02% 988
2020
Q4 		$90K Buy
+4,328
New +$108K 0.01% 1106

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GSA Capital Partners's RNTX Position: Q3 2021 in Review

GSA Capital Partners sold out of Rein Therapeutics (RNTX) in Q3 2021, closing a stake of 3,870 shares — an estimated $97K sold.

GSA Capital Partners first reported a position in RNTX in Q4 2020 and held it in 3 quarters. The position peaked at $119K in Q1 2021. 43 funds tracked by Wall St. Rank hold RNTX as of Q3 2021.

  • GSA Capital Partners reported no remaining Rein Therapeutics position as of Q3 2021 after selling out during the quarter.
  • GSA Capital Partners sold 3,870 Rein Therapeutics shares in Q3 2021, an estimated $97K.
  • GSA Capital Partners first reported a position in Rein Therapeutics in Q4 2020 and held it in 3 quarters.
  • GSA Capital Partners's Rein Therapeutics position peaked at $119K in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2021.

Based on GSA Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.